Inhibiting the enzymes that break down endocannabinoids (MAGL and FAAH) could raise natural painkiller levels and offer a targeted approach to migraine without the psychoactive effects of cannabis.
People interested in migraine treatment and endocannabinoid-based pain research.
Two enzyme targets (MAGL and FAAH) could boost natural pain relief
What the researchers found
MAGL and FAAH, the enzymes that degrade endocannabinoids, are distributed differently across brain regions involved in migraine pain. Blocking these enzymes raises levels of 2-AG and anandamide, which can reduce pain through both cannabinoid receptors and direct modulation of ion channels in pain neurons.
Why it matters
Current migraine treatments have limited effectiveness. Targeting the endocannabinoid system through enzyme inhibition could provide pain relief without the side effects and psychoactivity of plant-derived cannabis.
The numbers in context
Review covers two main enzyme targets (MAGL and FAAH) and two primary endocannabinoids (2-AG and anandamide) across multiple pain signaling pathways.
How the study worked
Thematic review synthesizing research on endocannabinoid degradation pathways, migraine pain signaling, and emerging enzyme inhibitors.
What this study cannot tell us
Much of the evidence comes from preclinical studies. Clinical trials of MAGL and FAAH inhibitors for migraine are still needed.
How to read the evidence
Thematic review of mostly preclinical research; clinical evidence for this approach in migraine is still lacking.
When this study was published
Published in 2022.
The bigger picture
Because endocannabinoids are produced "on demand" at sites of pain signaling, boosting their levels through enzyme inhibition could provide more targeted pain relief than administering external cannabinoids.
Questions still open
- Will MAGL and FAAH inhibitors prove safe and effective in human migraine trials? Could combining both types of inhibitors provide greater relief?
Common questions
How is this different from using cannabis for migraine?
Are these enzyme inhibitors available as treatments?
Read the original research
Inhibiting Endocannabinoid Hydrolysis as Emerging Analgesic Strategy Targeting a Spectrum of Ion Channels Implicated in Migraine Pain.
International journal of molecular sciences, 23(8)
Citation
Della Pietra, Adriana; Savinainen, Juha; Giniatullin, Rashid. (2022). Inhibiting Endocannabinoid Hydrolysis as Emerging Analgesic Strategy Targeting a Spectrum of Ion Channels Implicated in Migraine Pain.. International journal of molecular sciences, 23(8). https://doi.org/10.3390/ijms23084407
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk